In November 2011, Michelson Diagnostics, a Kent, England, UK-based medical device company, received a £1.912m investment.
Backers included Octopus Investments, Catapult Venture Managers and individual investors from London Business Angels.
The company is using the funds to expand sales and support infrastructure in USA (US operations are located in South Dartmouth, MA) and Europe.
Founded in 2006 and led by CEO Jon Holmes, Michelson Diagnostic designs innovative instruments using multi-beam optical coherence tomography solutions. The company’s first product – the VivoSight scanner – is based on its patented multi-beam optical coherence tomography (OCT) technology and is used by dermatologists to see below the surface of the skin, allowing them to gather additional information about their patient’s condition. The scanner has already won CE & Food and Drug Administration (FDA) regulatory clearance for clinical use in Europe and the USA, and has entered commercial service at dermatology clinics in USA and Germany.
FinSMEs
03/01/2012